Anzeige
Mehr »
Freitag, 17.10.2025 - Börsentäglich über 12.000 News
Silber durchbricht 50 US-Dollar - Vizsla Royalties zählt zu den größten Gewinnern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41HQ7 | ISIN: US80512Q5018 | Ticker-Symbol: 80W
NASDAQ
16.10.25 | 20:59
4,160 US-Dollar
-2,80 % -0,120
Branche
Chemie
Aktienmarkt
Sonstige
1-Jahres-Chart
N2OFF INC Chart 1 Jahr
5-Tage-Chart
N2OFF INC 5-Tage-Chart

Aktuelle News zur N2OFF Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
N2OFF Aktie jetzt für 0€ handeln
08.10.N2OFF regains compliance with Nasdaq minimum bid price requirement3
08.10.N2OFF, Inc. - 8-K, Current Report2
30.09.SciSparc-Aktie legt kräftig zu: N2OFF-Aktionäre genehmigen Übernahme von MitoCareX3
30.09.SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition3
30.09.SciSparc Stocks Surge 50% In Pre-Market After N2OFF Approves MitoCareX Acquisition3
29.09.SciSparc's subsidiary MitoCareX approved for acquisition by N2OFF shareholders; shares up 29%3
29.09.N2OFF shareholders approve acquisition of MitoCareX Bio from SciSparc1
29.09.SciSparc Ltd: SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer290TEL AVIV, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
► Artikel lesen
25.09.N2OFF, Inc. - 8-K, Current Report2
25.09.N2OFF-Aktionäre genehmigen Akquisition von MitoCareX Bio2
25.09.N2OFF stockholders approve MitoCareX Bio acquisition1
25.09.N2OFF Inc.: N2OFF Stockholders Approve Merger with Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer146Neve Yarak, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) ("N2OFF" and the "Company"), a cleantech company investing in solar energy assets based on the RTB (Ready to Build)...
► Artikel lesen
18.09.N2OFF, Inc. - 8-K, Current Report-
18.09.N2OFF announces 1-for-35 reverse stock split effective Sept 222
18.09.N2OFF to execute 1-for-35 reverse stock split2
18.09.N2OFF Inc.: N2OFF Announces Reverse Stock Split154Neve Yarak, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (FSE:80W) ("N2OFF" or the "Company"), a clean tech company engaged in sustainable solutions for the energy and agri-tech...
► Artikel lesen
18.09.N2OFF advances European solar and energy storage projects1
18.09.N2OFF Inc.: N2OFF Provides Business Update on Successful Execution of Solar and Energy Storage Initiatives Across Europe1
11.09.N2OFF Inc.: N2OFF to Expand its Melz Solar Project with Battery Storage1
09.09.N2OFF, Inc. - 8-K, Current Report1
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1